FERTILITY CAPSULE V (AMH, LH, FSH, PROLACTIN, E2, TSH)

Fertility Capsule V is a combined hormone blood-test panel that measures Anti-Müllerian Hormone (AMH), Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), prolactin, estradiol (E2) and Thyroid-Stimulating Hormone (TSH). Together, these markers provide information about ovarian reserve, menstrual-cycle regulation, ovulation, pituitary function, estrogen production and thyroid status.

Female fertility depends on the coordinated function of the hypothalamus, pituitary gland, ovaries, thyroid gland and reproductive organs. Hormonal imbalance at any point in this system may affect menstrual cycles or the release of an egg. This panel allows several important hormones to be assessed together, but it does not independently determine whether pregnancy will occur.

AMH is produced by developing follicles in the ovaries and is commonly used as an indicator of ovarian reserve. FSH and LH are produced by the pituitary gland and help regulate follicle development and ovulation. Estradiol is an estrogen produced mainly by the ovaries. Prolactin is another pituitary hormone, while TSH regulates thyroid-hormone production.

Benefits of the Test

• Evaluates six hormones relevant to reproductive and menstrual health.
• Provides information about ovarian reserve through AMH measurement.
• Supports assessment of follicle development and ovulation using FSH, LH and estradiol.
• Helps identify elevated prolactin that may interfere with menstrual cycles and ovulation.
• Checks TSH for possible thyroid dysfunction affecting reproductive health.
• Supports evaluation of irregular periods, absent periods and difficulty conceiving.
• May assist fertility specialists in planning further investigations or treatment.
• Provides baseline hormone values for monitoring fertility care when medically indicated.

Why Doctors Recommend This Test

A doctor may recommend Fertility Capsule V when a woman has difficulty becoming pregnant, irregular or absent menstrual periods, signs of reduced ovarian function or a medical history that may affect fertility. It may also be used before assisted-reproductive treatment to help evaluate ovarian reserve and the reproductive-hormone pattern.

AMH provides an estimate of the remaining follicle pool and can help predict how the ovaries may respond to fertility medicines. A lower AMH value may suggest reduced ovarian reserve, while a higher value may occur with a larger follicle pool or conditions such as polycystic ovary syndrome. AMH does not directly measure egg quality and cannot guarantee natural conception or predict the exact age of menopause.

FSH stimulates ovarian follicles, while LH contributes to ovulation and hormone production. Their concentrations change during the menstrual cycle. Abnormal patterns may occur with polycystic ovary syndrome, reduced ovarian function, hypothalamic or pituitary disorders and other reproductive conditions.

Estradiol supports follicle development and growth of the uterine lining. Measuring E2 with FSH may help doctors interpret ovarian activity more accurately. The menstrual-cycle day is important because estradiol, LH and FSH vary naturally throughout the cycle.

High prolactin can suppress reproductive-hormone signalling and may cause irregular periods, absent periods, infertility or unexpected breast-milk production. Prolactin may rise temporarily because of stress, exercise, sleep or breast stimulation, so a mildly elevated result may require confirmation.

Thyroid dysfunction can affect menstrual regularity, ovulation and pregnancy. An abnormal TSH result may lead to additional thyroid testing, such as free T4 and thyroid antibodies, depending on the clinical situation.

Preparation Before Test

Fasting is generally not required unless the doctor or laboratory provides specific instructions. Because hormone levels may be influenced by collection timing, follow the recommended date and time carefully. FSH, LH and estradiol are often measured during a particular phase of the menstrual cycle, frequently in the early follicular phase, but the appropriate day depends on the clinical purpose.

AMH usually varies less across the menstrual cycle than FSH, LH and estradiol and may often be measured on any cycle day. However, the treating doctor should determine the appropriate timing for the complete panel.

Prolactin may change during the day and can rise with emotional stress, strenuous exercise, sleep, sexual activity and breast stimulation. The laboratory or doctor may recommend a morning sample after the patient has been awake and rested for a specified period.

Inform the doctor about hormonal contraceptives, fertility medicines, thyroid medicines, antipsychotic medicines, antidepressants, steroids, biotin supplements and all other treatments. These may influence one or more results. Do not discontinue prescribed medicines unless instructed by the treating doctor.

Provide the date of the last menstrual period, usual cycle length, pregnancy status and details of fertility treatment. A healthcare professional will collect a blood sample from a vein in the arm. The collection usually takes only a few minutes.

Normal Reporting Time

The complete Fertility Capsule V report is commonly available within 24–48 hours after the laboratory receives a suitable blood sample. Individual components may be completed at different times. Turnaround time can vary according to sample collection time, analytical schedule, quality-control checks and result verification.

Who Should Take This Test?

This panel may be appropriate for women experiencing difficulty conceiving, irregular or absent periods, suspected ovulation problems, symptoms of polycystic ovary syndrome or possible reduced ovarian reserve. It may also be requested before fertility treatment, egg freezing or assisted-reproductive procedures.

Doctors may recommend hormonal assessment for women with early menopausal symptoms, previous ovarian surgery, chemotherapy or radiation exposure, a family history of early menopause, unexpected breast discharge or symptoms suggesting thyroid dysfunction.

This test should be performed according to medical advice. It is not a complete fertility evaluation by itself. Depending on the clinical situation, additional assessment may include pelvic ultrasound, antral follicle count, progesterone testing, tubal-patency testing and semen analysis of the male partner.

Detailed Information

AMH is produced by granulosa cells in small developing ovarian follicles. It is useful for estimating ovarian reserve and anticipating ovarian response during fertility treatment. A low result does not mean that natural pregnancy is impossible, and a high result does not prove normal fertility.

FSH encourages ovarian follicles to grow. When ovarian response decreases, the pituitary gland may produce more FSH. Estradiol can influence FSH through feedback mechanisms; therefore, both results may be evaluated together. Reference values depend strongly on age, menstrual phase and laboratory method.

LH helps trigger ovulation and supports formation of the corpus luteum after ovulation. An LH surge normally occurs during the middle of the menstrual cycle. A single LH measurement outside the appropriate clinical context cannot confirm that ovulation has occurred.

Estradiol is the main biologically active estrogen during reproductive years. Its concentration changes as follicles develop and after ovulation. Abnormal levels may be associated with ovarian, pituitary or other hormonal conditions, but the result is not diagnostic when considered alone.

Prolactin is produced by the pituitary gland and is best known for supporting milk production. Persistently high prolactin may be associated with medicines, pregnancy, hypothyroidism, kidney disease or a pituitary condition. Further investigation depends on the degree of elevation and the patient's symptoms.

TSH is released by the pituitary gland to regulate thyroid-hormone production. Both underactive and overactive thyroid conditions may influence menstruation and fertility. TSH must be interpreted using the laboratory reference interval and, when relevant, pregnancy- or preconception-specific clinical targets.

Hormone reference ranges vary according to age, menstrual-cycle phase, pregnancy status, medicine use and analytical method. Results should be interpreted by a gynaecologist, fertility specialist or other qualified healthcare professional together with symptoms, ultrasound findings and reproductive history.